Evaluating chidamide for maintaining treatment in PTCL patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the efficacy and safety of chidamide as a first-line maintenance therapy for patients diagnosed with peripheral T-cell lymphoma (PTCL). It involves a retrospective analysis of patient data collected from those who received chidamide after initial treatment. The study will analyze various factors including patient demographics, previous treatment regimens, and results from auxiliary examinations such as blood tests and imaging studies to determine the outcomes associated with chidamide therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment.

Exclusion Criteria:

* (1) Patients with other types of lymphomas; (2) Pregnant women.

Where it's running

• Hematological Department, People's Hospital of Jiangsu Province
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: wei xu
• Email: xuwei10000@hotmail.com
• Phone: +862568302182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nanobody-based CAR-T therapy for relapsed T-cell leukemia and lymphoma

  This study is testing a new type of CAR-T therapy using nanobodies to see if it can help people with relapsed T-cell leukemia or lymphoma feel better and live longer.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06874946

• Combination treatment for relapsed Peripheral T-Cell Lymphoma

  This study is testing a new combination treatment for people with relapsed Peripheral T-Cell Lymphoma to see if it works better than standard single-agent therapies.

  Recruiting at 5 sites Phase 2 University of Virginia · Long Beach, California and 5 other locations · NCT04747236

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Off-clamp, sutureless robot-assisted partial nephrectomy vs conventional robot-assisted partial nephrectomy

  This trial tests whether removing a small kidney tumor without clamping the blood supply and without stitching the kidney bed preserves kidney function better than the standard robot-assisted surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07888608

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.